Ann: Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer, page-51

I’m a little bit disappointed. Not so much with the share price over the past two days,  but with the posters on this thread. No one appears to have picked up on the independent clinician’s comments about the two additional indications that show great promise. This is what JF means when she talks of adding value. Sooner or later that value will be recognised.
Meanwhile, the SP is just absurd. Perhaps the market is saying they have had enough of the current CEO (and chairman), but she will be retiring next year, after a controlled handover to the new incumbent, as it should be. Perhaps the market is looking for a CR at a cheap price. Unlikely to happen. Perhaps the market is very low in confidence right now and biotech is coping it most. Probably (For example, take a look at Imugene. Great potential but down from 60c to 4.2c in about a year).
The only thing that will lift the SP is a good deal. I am sure management are working hard to achieve that, contrary to what some of our posters think and say.